An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)

American Journal of Translational Research

Volumn 5, Issue 2, 2013, Pages 139-154

  Ling, Xiang ^a   Li, Fengzhi ^a,b  

^a Departments of Pharmacology and Therapeutics   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antitumor activity; FL118; Human tumor animal model; Intraperitoneal (i.p.); Intravenous (i.v.); Maximum tolerated doses (MTD)

Indexed keywords

ANTINEOPLASTIC AGENT; FL 118; FL118; INHIBITOR OF APOPTOSIS PROTEIN 2; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; MAXIMUM TOLERATED DOSE; MOUSE; NEOPLASM; NONHUMAN; NUDE MOUSE; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR XENOGRAFT;

ANIMALIA;

EID: 84875772988     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
2. Altieri DC. Survivin and IAP proteins in celldeath mechanisms. Biochem J 2010; 430: 199-205.
3. Li F and Ling X. Survivin Study: An update of "What is the next wave?" J Cell Physiol 2006; 208: 476-486.
4. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R and Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881-4887.
5. Carter BZ, Mak D, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W and Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: Targeting survivin overcomes Imatinib resistance and increases Imatinib sensitivity in Imatinib responsive CML cells. Blood 2006; 107: 1555-1563.
6. Peng X, Karna P, Cao Z, Jiang B, Zhou M and Yang L. Cross-talk between epidermal growth factor receptor and HIF-1 signal pathways increases resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 2006; 281: 25903-25914.
7. Wu J, Apontes P, Song L, Liang P, Yang L and Li F. Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res 2007; 35: 2390-2402.
8. Oh SH, Jin Q, Kim ES, Khuri FR and Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 2008; 14: 1581-1589.
9. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T and Li F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNAbinding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 2005; 280: 9745-9751.
10. Fetz V, Bier C, Habtemichael N, Schuon R, Schweitzer A, Kunkel M, Engels K, Kovacs AF, Schneider S, Mann W, Stauber RH and Knauer SK. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 2009; 124: 2033-2041.
11. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA and Jove R. Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells. Clin Cancer Res 2006; 12: 11-19.
12. Moriai R, Tsuji N, Moriai M, Kobayashi D and Watanabe N. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 2008; 117: 261-271.
13. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F and Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009; 15: 1326-1334.
14. Zhang M, Latham DE, Delaney MA and Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005; 24: 2474-2482.
15. Yoo J and Lee YJ. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligandmediated apoptosis in hormone-refractory prostate cancer cells through survivin downregulation. Mol Pharmacol 2007; 72: 1586-1592.
16. Roca H, Varsos Z and Pienta KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via PI3K/AKT-dependent survivin upregulation. J Biol Chem 2008; 283: 25057-25073.
17. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D and Sakr WA. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009; 69: 4468-4475.
18. Wang S, Huang X, Lee CK and Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010; 29: 4225-4236.
19. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Koo HH, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Muschen M and Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191-2199.
20. Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M and Nakagawa K. Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin. Mol Cancer Ther 2012; 11: 204-213.
21. Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, Kim EG, Lee CW and Choi KS. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin. Carcinogenesis 2012; 33: 492-500.
22. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH and Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-3524.
23. Song L, Coppola D, Livingston S, Cress D and Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005; 4: 267-276.
24. Wirth T, Kuhnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L and Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005; 65: 7393-7402.
25. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW and Shen Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979.
26. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P and Shore GC. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apopto sis. Proc Natl Acad Sci U S A 2007; 104: 19512-19517.
27. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD and El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12: 66-80.
28. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R and Aoudjit F. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 2008; 6: 42-52.
29. Boisvert-Adamo K, Longmate W, Abel EV and Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 2009; 7: 549-556.
30. Hauck P, Chao BH, Litz J and Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009; 8: 883-892.
31. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S and Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 2009; 8: 2084-2096.
32. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'Diaye M, Denoyelle C, Gauduchon P and Poulain L. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 2009; 8: 3162-3170.
33. Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA and Pieters R. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010; 115: 1018-1025.
34. Li QF, Yan J, Zhang K, Yang YF, Xiao FJ, Wu CT, Wang H and Wang LS. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1. Biochem Biophys Res Commun 2011; 405: 31-36.
35. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, Van Oers MH and Eldering E. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res 2011; 18: 487-98.
36. Holcik M, Yeh C, Korneluk RG and Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000; 19: 4174-4177.
37. Zhang J, Li Y and Shen B. Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia 2002; 16: 2163-2165.
38. Amantana A, London CA, Iversen PL and Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004; 3: 699-707.
39. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP and Kuo ML. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaBdependent XIAP up-regulation. J Biol Chem 2004; 279: 24015-24023.
40. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC and Glinsky GV. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005; 65: 2378-2386.
41. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH and Lu GC. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005; 12: 509-514.
42. Braeuer SJ, Buneker C, Mohr A and Zwacka RM. Constitutively activated nuclear factorkappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006; 4: 715-728.
43. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP and McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007; 67: 1430-1435.
44. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM and Fulda S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68: 7956-7965.
45. Aird KM, Ghanayem RB, Peplinski S, Lyerly HK and Devi GR. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther 2010; 9: 1432-1442.
46. Yuan H, Fu F, Zhuo J, Wang W, Nishitani J, An DS, Chen IS and Liu X. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c IAP2 gene expression and confer resistance to apoptosis. Oncogene 2005; 24: 5069-5078.
47. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C and Sasaki I. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009; 100: 903-913.
48. Petersen SL, Peyton M, Minna JD and Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci U S A 2010; 107: 11936-11941.
49. Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG and Lee H. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/ phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res 2010; 16: 5200-5210.
50. Nagata M, Nakayama H, Tanaka T, Yoshida R, Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A and Shinohara M. Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 2011; 105: 1322-1330.
51. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM and Li F. A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity. PLOS ONE 2012; 7: e45571.
52. Li F, Ling X, Cao S. Novel Formulations of Water-Insoluble Chemical Compounds and Methods of Using a Formulation of Compound FL118 for Cancer Therapy. Filed by Roswell Park Cancer Institute at the United States Patent and Trademark Office (USPTO), non-provisional patent in pending, PCT/US11/58558, 2011.
53. Ruckert F, Samm N, Lehner AK, Saeger HD, Grutzmann R and Pilarsky C. Simultaneous gene silencing of Bcl-2, XIAP and Survivin resensitizes pancreatic cancer cells towards apoptosis. BMC Cancer 2010; 10: 379.
54. Montazeri Aliabadi H, Landry B, Mahdipoor P and Uludag H. Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Mol Pharm 2011; 8: 1821-1830.
55. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH and Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A 1997 Sep 16; 94: 10057-62.
56. Bhattacharya S, Ray RM and Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyaminedepleted cells. Biochem J 2005; 392: 335-344.
57. Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, Ripoche H, Khabir A, Tsao SW, Bosq J, Lo KW and Busson P. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 2008; 10: 1183-1194.
58. Jang BC, Paik JH, Jeong HY, Oh HJ, Park JW, Kwon TK, Song DK, Park JG, Kim SP, Bae JH, Mun KC, Suh MH, Yoshida M and Suh SI. Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem pharmacol 2004; 68: 263-274.
59. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS and Kwon TK. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006; 5: 2737-2746.
60. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM and Byrd JC. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007 Apr 1; 13: 2144-50.
61. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R and Aoudjit F. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 2008 Jan; 6: 42-52.
62. Li F. Discovery of Survivin Inhibitors and Beyond: FL118 as a Proof of Concept. International Review of Cell and Molecular Biology 2013; 305.
63. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M and Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
64. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human can cer cell lines and xenograft models. Cancer Sci 2010; 102: 614-621.
65. Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011; 35: 787-792.
66. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-6504.
67. Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M and Nakagawa K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010; 103: 36-42.
68. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H and Sasamata M. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011; 22: 454-462.
69. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A and Antonia S. Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. J Clin Oncol 2008; 26: 5198-5203.
70. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011; 29: 161-166.
71. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y and Nakagawa K. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-3880.
72. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2011; 23: 968-973.
73. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
74. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT and Shamsili S. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-3134.
75. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 2012; 3: 179-97.
76. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL and Newton DL. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 2012 Jul; 70: 207-12.
77. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
78. Skoufias DA, Mollinari C, Lacroix FB and Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 2000; 151: 1575-1582.
79. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL and Choo KH. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-1328.
80. Li F. Survivin Study: What is the next wave? J Cell Physiol 2003; 197: 8-29.
81. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127.
82. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
83. Reed JC and Reed SI. Survivin' cell-separation anxiety. Nat Cell Biol 1999; 1: E199-200.
84. Li F and Brattain MG. Role of the Survivin Gene in Pathophysiology. Am J Pathol 2006; 169: 1-11.
85. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L and Brattain MG. Differential regulation of survivin expression and apoptosis by vitamin D(3) compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 2005; 24: 1385-1395.
86. Tang L, Ling X, Liu W, Das GM and Li F. Transcriptional inhibition of p21(WAF1/CIP1) gene (CDKN1) expression by survivin is at least partially p53-dependent: Evidence for survivin acting as a transcription factor or co-factor. Biochem Biophys Res Commun 2012 May 4; 421: 249-54.
87. Zhang M, Yang J and Li F. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res 2006; 25: 391-402.
88. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P and Rottenberg S. Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010 Feb 15; 70: 1700-10.